[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"stock-detail-ELDN":3,"homepage-market-summary":31,"stock-news-ELDN":173},{"ticker":4,"date":5,"profile":6,"dividend":9,"quote":15},"ELDN","2026-10-02",{"name":7,"exchange":8,"sector":9,"industry":10,"description":11,"ceo":9,"employees":12,"headquarters":13,"founded":9,"is_fund":14,"issuer":9,"category":9},"Eledon Pharmaceuticals, Inc. Common Stock","Nasdaq",null,"PHARMACEUTICAL PREPARATIONS","Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.","33","Irvine, CA",false,{"close":16,"open":17,"high":18,"low":19,"prev_close":20,"change":21,"percent_change":22,"volume":23,"transactions":24,"vwap":25,"high_52w":26,"low_52w":27,"avg_volume_52w":28,"range_52w_percent":29,"record_count":30},2.49,2.48,2.55,2.42,2.435,0.055,2.26,960372.332434,7300,2.4785,4.6,1.35,1430232.372115532,35.1,3028,{"status":32,"indices":33,"watchlist":77,"sectors":99,"benchmarks":155},"success",[34,42,49,56,63,70],{"symbol":35,"name":36,"price":37,"change":38,"pct_change":39,"is_up":40,"sparkline":41,"date":5},"SPX","S&P 500",7722.72,56.27,0.73,true,"0.0,5.0 2.3,8.0 4.6,10.4 6.9,13.4 9.3,9.1 11.6,11.5 13.9,13.8 16.2,16.0 18.5,10.3 20.8,9.5 23.2,2.0 25.5,2.0 27.8,5.9 30.1,6.0 32.4,3.4 34.7,7.3 37.1,8.2 39.4,9.4 41.7,8.5 44.0,4.8",{"symbol":43,"name":44,"price":45,"change":46,"pct_change":47,"is_up":40,"sparkline":48,"date":5},"NDX","NASDAQ 100",30807.93,306.37,1,"0.0,11.5 2.3,11.7 4.6,12.4 6.9,14.8 9.3,12.8 11.6,14.6 13.9,16.0 16.2,15.9 18.5,12.2 20.8,10.7 23.2,4.4 25.5,2.6 27.8,4.5 30.1,4.5 32.4,3.5 34.7,6.0 37.1,5.5 39.4,5.0 41.7,4.3 44.0,2.0",{"symbol":50,"name":51,"price":52,"change":53,"pct_change":54,"is_up":40,"sparkline":55,"date":5},"DJI","DOW JONES",51177,250,0.49,"0.0,2.0 2.3,5.5 4.6,7.8 6.9,9.5 9.3,6.7 11.6,7.5 13.9,9.4 16.2,12.9 18.5,11.1 20.8,11.7 23.2,9.6 25.5,10.7 27.8,12.6 30.1,13.5 32.4,10.8 34.7,12.8 37.1,13.5 39.4,16.0 41.7,15.9 44.0,14.5",{"symbol":57,"name":58,"price":59,"change":60,"pct_change":61,"is_up":40,"sparkline":62,"date":5},"COMP","NASDAQ Composite",27190.86,319.27,1.19,"0.0,10.2 2.3,11.1 4.6,13.0 6.9,14.9 9.3,12.1 11.6,13.7 13.9,16.0 16.2,16.0 18.5,11.1 20.8,10.0 23.2,3.4 25.5,2.0 27.8,5.4 30.1,5.4 32.4,3.9 34.7,6.7 37.1,6.9 39.4,6.2 41.7,6.1 44.0,2.6",{"symbol":64,"name":65,"price":66,"change":67,"pct_change":68,"is_up":40,"sparkline":69,"date":5},"RUT","RUSSELL 2000",2815.2,25,0.9,"0.0,2.0 2.3,3.0 4.6,6.1 6.9,8.4 9.3,7.5 11.6,8.8 13.9,10.4 16.2,11.3 18.5,10.2 20.8,11.2 23.2,10.1 25.5,8.8 27.8,12.9 30.1,13.1 32.4,12.8 34.7,14.4 37.1,15.1 39.4,16.0 41.7,15.1 44.0,13.2",{"symbol":71,"name":72,"price":73,"change":74,"pct_change":75,"is_up":14,"sparkline":76,"date":5},"VIX","CBOE VIX",15.31,-1.08,-6.59,"0.0,14.8 2.3,10.2 4.6,7.3 6.9,2.0 9.3,9.7 11.6,4.9 13.9,4.5 16.2,2.5 18.5,11.3 20.8,13.7 23.2,13.5 25.5,16.0 27.8,12.3 30.1,10.4 32.4,13.5 34.7,8.8 37.1,8.9 39.4,7.8 41.7,7.6 44.0,11.8",[78,85,92],{"symbol":79,"name":80,"price":81,"change":82,"pct_change":83,"is_up":40,"sparkline":84,"date":5},"NVDA","NVIDIA Corp",233.95,3.09,1.34,"0.0,16.0 7.3,15.3 14.7,9.6 22.0,12.1 29.3,10.3 36.7,6.6 44.0,2.0",{"symbol":86,"name":87,"price":88,"change":89,"pct_change":90,"is_up":40,"sparkline":91,"date":5},"AAPL","Apple Inc",333.69,3.37,1.02,"0.0,8.2 7.3,2.0 14.7,5.2 22.0,16.0 29.3,11.7 36.7,14.9 44.0,10.9",{"symbol":93,"name":94,"price":95,"change":96,"pct_change":97,"is_up":40,"sparkline":98,"date":5},"TSLA","Tesla Inc",370.59,16.48,4.65,"0.0,2.0 7.3,5.3 14.7,13.4 22.0,16.0 29.3,14.9 36.7,15.3 44.0,6.1",[100,105,110,115,120,125,130,135,140,145,150],{"name":101,"etf":102,"change":103,"price":104,"is_up":40},"Technology","XLK",1.01,199.81,{"name":106,"etf":107,"change":108,"price":109,"is_up":40},"Financials","XLF",0.06,53.49,{"name":111,"etf":112,"change":113,"price":114,"is_up":14},"Healthcare","XLV",-0.01,166.18,{"name":116,"etf":117,"change":118,"price":119,"is_up":40},"Consumer Cycl","XLY",1.13,110.04,{"name":121,"etf":122,"change":123,"price":124,"is_up":40},"Consumer Staples","XLP",0.25,80.53,{"name":126,"etf":127,"change":128,"price":129,"is_up":40},"Energy","XLE",0.4,62.95,{"name":131,"etf":132,"change":133,"price":134,"is_up":40},"Industrials","XLI",0.78,169.95,{"name":136,"etf":137,"change":138,"price":139,"is_up":40},"Materials","XLB",0.66,48.86,{"name":141,"etf":142,"change":143,"price":144,"is_up":40},"Real Estate","XLRE",0.32,40.81,{"name":146,"etf":147,"change":148,"price":149,"is_up":40},"Utilities","XLU",0.38,39.83,{"name":151,"etf":152,"change":153,"price":154,"is_up":40},"Comm Services","XLC",0.35,110.32,[156,161,165,169],{"ticker":157,"name":158,"price":159,"change":160,"is_up":40},"SPY","SPDR S&P 500 ETF",769.64,0.74,{"ticker":162,"name":163,"price":164,"change":90,"is_up":40},"QQQ","Invesco QQQ Trust",749.58,{"ticker":166,"name":167,"price":168,"change":54,"is_up":40},"DIA","SPDR Dow Jones ETF",511.1,{"ticker":170,"name":171,"price":172,"change":68,"is_up":40},"IWM","iShares Russell 2000",281.52,{"ticker":4,"count":174,"articles":175},8,[176,182,187,193,199,204,208,213],{"title":177,"link":178,"pubDate":179,"description":180,"source":181},"No reported rejections followed Eledon’s drug after six months, versus seven for tacrolimus. Phase 3 is expected in Q4 2026. - Stock Titan","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiuwFBVV95cUxOY0QxNFJNTko5azdndUQyOFdqSVRtQ3VDSHJLajliSmJrNmhtb2V1TXhBOE9yVmtCdWg1c3VERGxNb0g4ZFo0czVmV1RfN3Flb2JXaXhuekh1ZjRyaWFmYnVBMGZGa1N1c2trY1EwNjlhSjVTYnlfQVViU3pFeS1QVmp2LW1DX2NLODhmdHdnTDNpaFM2Q3oxRnFPbTVmWTRxTGEzZDJlcnZBa0RkdVNpTGZ2cVBjVEF4RDBN?oc=5","Tue, 22 Sep 2026 07:00:00 GMT","No reported rejections followed Eledon’s drug after six months, versus seven for tacrolimus. Phase 3 is expected in Q4 2026. Stock Titan","Stock Titan",{"title":183,"link":184,"pubDate":179,"description":185,"source":186},"Eledon Pharmaceuticals, Inc. (ELDN) Presents at International Congress of The Transplantation Society 2026 - Slideshow (NASDAQ:ELDN) 2026-09-22 - Seeking Alpha","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiygFBVV95cUxQQnlrLVFlLVcyekRndW4tQ0JZN1JNS1hDak1uVVN4eHh0bGctaGdOMWI4OXBtNG5MQzdMZ2pra2hDMVh1bld1S2NYZTN0X0lPNmlTTVIyNm5DNnVuM01qbDlXa2dyTlI0bW5sbVJmOG83cmxTVlVBd3l1UXlSTVJsMXc3cWtGUlcyRjZoa1c1eG9VdzBlVHIwM0Z2NlZfeUdwVF9BU2ptQS1EeUVySG4xMFlqWThhbm9GUEVpcG1WMVNKQlRZaTZXdldn?oc=5","Eledon Pharmaceuticals, Inc. (ELDN) Presents at International Congress of The Transplantation Society 2026 - Slideshow (NASDAQ:ELDN) 2026-09-22 Seeking Alpha","Seeking Alpha",{"title":188,"link":189,"pubDate":190,"description":191,"source":192},"Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN), Viking Therapeutics (VKTX) and Amgen (AMGN) - The Globe and Mail","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMipwJBVV95cUxONTRzWnEzcFEzb1o5VUZ1eVBKcFV6QVlyS0hTUlgycU8xZHFPNjkzNW1xc1oxQ2RueDdtSTlOUHFVbTNsTXhoWEFad01wUDZpOG1SbDBVOWJNcjVIaDMxTE1EWkVJLWl6VEpFU0s4a2FaUG12ekpXajl6eU5PaXJycUVYVjlvYjNlaXBZUFRaVGZKVEwyMGhjV1dObGFjQnl6Qy1kakJkdmtaUlRIX20wa1dQbkk3S3haemdBVHJjZmw2bTdhbDdWWjhoeUUtb2NrVnppOU5lei1idnFZVWt6WHpPejdyeDZySHk5SV9yYzdRUF9ncDNLSUJCejhEak4tVjNvM3N3ZWptMUhuTkZucEY1OEU3YWV3eExfdmVPTGhONTNzVm04?oc=5","Wed, 23 Sep 2026 07:00:00 GMT","Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN), Viking Therapeutics (VKTX) and Amgen (AMGN) The Globe and Mail","The Globe and Mail",{"title":194,"link":195,"pubDate":196,"description":197,"source":198},"Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society - markets.businessinsider.com","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMinAJBVV95cUxPZkZKMTcyWUlRTnlzbC0tZEhrX1JuWDBhNnMyMjRIZG83Qk9oQkNWblgtMzZrUWlXZ3l4TWg1azJzLWRqVldwdS1SRWEtQVBZc0VOdkV6WWZyU2JpZzdSSnRiaWtXc2JNQkIxWGpNcE9hbHI5c3JQci04d1BDU2U4eWZUczlFRWpSTDlqZW84dEphczJNM1dCc05zNElDQ1hJd1o4d1hyUjdUSHh5NEl1Z0tTV09WUENZcVpzT3pVcFFreEtqQndvSzBvWGtjS0hwYnJMeWJqT2h4VDhkdXdabGhfUzYtMlZTU3JTNXNZZlc4d1BpaFB4SzQtdFI4eW55Rnh2X3BXSXVtcmJITnNOS0FSLUg2anJaUjZLdg?oc=5","Tue, 22 Sep 2026 12:14:05 GMT","Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society markets.businessinsider.com","markets.businessinsider.com",{"title":200,"link":201,"pubDate":190,"description":202,"source":203},"Noble Financial Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $10 - Moomoo","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiwwFBVV95cUxNYWJPUUNjOUo1aGYyaEF0X3ZyT3haSkxLUjV0NWJWeW9TcmlMQkZrSHVFT2E1X0VkTWdpQWVkNEE2dGxRaTNZeW02MkdJTXozTzZFQlE5eF9wY054U2puOGQ5Y1JZZC1HbGZmQVVzRU1vV2tzRFV2MGFpdEQ5ME1KQWxJUTNXSmdmYXA2ajN2U1NqOGZQUUJVNHFaVE9sWW9sY1BoZTdtMDFENXZReWgwTUFVMHlOdnZSWFhxLVF1WUlfRE0?oc=5","Noble Financial Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $10 Moomoo","Moomoo",{"title":205,"link":206,"pubDate":179,"description":207,"source":186},"Eledon updates mid-stage trial data for lead drug (ELDN:NASDAQ) - Seeking Alpha","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiiwFBVV95cUxOQlNmc29CTk9lckU4RGV3NldZakZ6Sl9rMjFPWEJmSENUSWxFeWV6eDI4TFpRUHlQd0tYZ2o0MlBkcEVkNFk1N2N3LXZSWnNtV0NTMzlXTS1tNW1kakJmMmdEbHUtZGN2Y2pFQ3lxMTRlWDl0ZzNkX2NPa2F0eUN5Mjl0VWpqUDdsWlJR?oc=5","Eledon updates mid-stage trial data for lead drug (ELDN:NASDAQ) Seeking Alpha",{"title":209,"link":210,"pubDate":211,"description":212,"source":192},"Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN), Lexeo Therapeutics, Inc. (LXEO) and Edgewise Therapeutics (EWTX) - The Globe and Mail","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiwAJBVV95cUxOUXVWTzhzdERHT3hpLXFyYmVZZk9SMDV6UzR4VWE3QTNBekdNNEQxLTRBemxaeW5DWXhyTHJDVEZLaVI3V3U4Uk4wRTVsWjEwUlZ4TUlqWXBldUZ2bWk3b1hBckhBNEVITk9TVl9Lakl4NGIxaGxkN2RfNk1BV1BnaWhOVkxUWHRRelVnSUw4ZGpkMG5jVWxWVkFFRHhmT0R1ZmkxMEJHeVRaRkVlbUdiTGV1Q191QzMtVUs3Q0tERklpT24wc2VFNGVmRkFJSURsN3Y5bmhYcmVMUUE0ZUxRUXBSWW1GQ1EzbzdibUZpU0xJb0ZPdzJMY0RPQWMxVmN1LTFNNTRFb202V0VFU1RPWWxnN0E0M2NScmFQbVFucTVtcXVDdndtUUlPM0o1NWZGdWdsMm0xZkRreEJGb09yRg?oc=5","Thu, 24 Sep 2026 13:12:00 GMT","Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN), Lexeo Therapeutics, Inc. (LXEO) and Edgewise Therapeutics (EWTX) The Globe and Mail",{"title":214,"link":215,"pubDate":216,"description":217,"source":218},"Eledon Pharmaceuticals, Inc. Presents Updated Long-Term Phase 2 BESTOW Extension Study Results For Tegoprubart And Announces FDA Fast Track Designation - marketscreener.com","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMi5gFBVV95cUxNbXdLY0VBTHRaWnRDbjdwdVBTSFFEdDcyX3JJS0FzMkl5UlpSZHo3ZzN3cjh4QXpad1k3alllMnJkaWlqaGQ3VHRrSWRadVE2ZVJrWDFsTExYd0E2blBYQWZkb3g1dW5SZHl6eTVGTDhuc0NfelUwaEJWSzJqNW5yS01JTjNKWWxOWkFHLS1QbF9JSEx2TFZPWHozYk5FS1dFLTFEVDY3VFNTdUVleG8yenhkNEd0VGRsRjQyTHFSeGlIX05ja2FSY2c4VjhJT09Pc1ZfVWxjMlA4ZDlXVC03YlpGS0wtUQ?oc=5","Tue, 22 Sep 2026 11:00:00 GMT","Eledon Pharmaceuticals, Inc. Presents Updated Long-Term Phase 2 BESTOW Extension Study Results For Tegoprubart And Announces FDA Fast Track Designation marketscreener.com","marketscreener.com"]